Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.09.2020 | Case report

Dabigatran etexilate/ibrutinib

Atrial fibrillation, bruising and bleeding: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lewicka E, et al. Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation. Kardiologia Polska 78: 454-457, No. 5, 25 May 2020. Available from: URL: http://doi.org/10.33963/KP.15255 Lewicka E, et al. Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation. Kardiologia Polska 78: 454-457, No. 5, 25 May 2020. Available from: URL: http://​doi.​org/​10.​33963/​KP.​15255
Metadaten
Titel
Dabigatran etexilate/ibrutinib
Atrial fibrillation, bruising and bleeding: 2 case reports
Publikationsdatum
01.09.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-83463-y

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Ranibizumab

Case report

Abciximab

Case report

Dinitrophenol